PT - JOURNAL ARTICLE AU - Vignali, Valentina AU - Hoff, Tobi AU - de Vries-Idema, Jacqueline AU - Huckriede, Anke AU - van Dijl, Jan Maarten AU - van Rijn, Patrick TI - An efficient UV-C disinfection approach and biological assessment strategy for microphones AID - 10.1101/2022.07.09.22277021 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.09.22277021 4099 - http://medrxiv.org/content/early/2022/07/10/2022.07.09.22277021.short 4100 - http://medrxiv.org/content/early/2022/07/10/2022.07.09.22277021.full AB - Hygiene is a basic necessity to prevent infections and though it is regarded as vital in general, its importance has been stressed again during the pandemic. Microbes may spread through touch and aerosols and thereby find their way from host to host. Cleaning and disinfection of possibly contaminated surfaces prevents microbial spread thus reducing potential illnesses. One item that is used by several people in a way that promotes close contact by touch and aerosol formation is the microphone. A microphone is a complex piece of equipment with respect to shape and various materials used to fabricate it and, hence, its disinfection is challenging. A new device has been developed to efficiently sterilize microphones using UV-C and the biological assessment has been done to identify its efficacy and translatability. For this investigation, a contamination procedure was developed using M13 bacteriophage as a model to illustrate the effectiveness of the disinfection. The susceptibility to UV-C irradiation of M13 in solution was compared to that of PR8 H1N1 influenza virus, which has a similar UV-C susceptibility as SARS-CoV-2. It was found that 10 min of UV-C treatment reduced the percentage of infectious M13 by 99.3% based on whole microphone inoculation and disinfection. UV-C susceptibility of M13 and influenza in suspension were found to be very similar, indicating that the microphone sterilization method and device function are highly useful and broadly applicable.Competing Interest StatementThe authors declare the following conflict of interests: P. van Rijn also is co-founder, scientific advisor, and shareholder of BiomACS BV, a biomedical-oriented screening company. This re-search was partly funded by LAC Labs GmbH (T.H.) but did not influence the scientific merits or outcomes in any way. The other authors declare no conflicts of interest.Funding StatementThis research was partially funded by LAC Labs GmbH, and the European Unions Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 713482 (ALERT Cofund)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors